Diamyd Medical AB Reports Third Quarter Financial Results
Stockholm, June 25, 2025 — Diamyd Medical AB, a biotechnology company specializing in autoimmune diabetes treatments, has released its financial results for the third quarter of the fiscal year 2024/2025. The company, listed on the Swedish Stock Exchange, reported a decrease in its operating result, with no revenue generated during this period.
Financial Overview
For the third quarter, Diamyd Medical’s operating result was reported at -48.1 million SEK, a decline from the previous year’s -42.3 million SEK. The net result also reflected a loss of -43.9 million SEK. The company’s close price on May 29, 2025, was 8.88 SEK, with a market capitalization of 1.27 billion SEK. The 52-week high was 25 SEK, reached on July 30, 2024, while the low was 7.5 SEK, recorded on April 21, 2025. The price-to-earnings ratio stood at -5.6.
Company Focus and Developments
Despite the financial losses, Diamyd Medical remains focused on its core projects. The company is advancing its combination therapies for autoimmune diabetes, including Diamyd, a Phase IIb clinical trial diabetes vaccine, and Remygen, a regenerative and immunomodulatory therapy in phases Ib/IIa for both autoimmune and type 2 diabetes treatment.
In a recent statement, the CEO of Diamyd Medical highlighted the anticipated completion of recruitment for the Diagnode-3 trial within the year. This trial is a significant step in the company’s research and development efforts.
Market Context
On the broader market front, the Stockholm Stock Exchange is expected to open with minimal changes on Wednesday, June 25, 2025. The market’s focus includes discussions at the NATO summit in The Hague regarding increased defense spending, which may influence investor sentiment.
Upcoming Reports and Events
Diamyd Medical is scheduled to present its quarterly report at 11:00 AM on the same day. Investors and stakeholders are closely monitoring these developments as they assess the company’s future prospects in the biotechnology sector.
For further updates, stakeholders are encouraged to follow Diamyd Medical’s announcements and the broader market trends impacting the health care and biotechnology industries.